A Medical Device Daily

Hospira (Lake Forest, Illinois), a pharmaceutical and medication delivery company, reported that it has acquired the EndoTool business from MD Scientific (both Charlotte, North Carolina). Terms of the purchase were not disclosed.

EndoTool is the developer of a glucose management system, described as an FDA-cleared software system that helps establish and maintain glycemic control in acute, critical care and operating room settings by calculating the dose of intravenous insulin needed to control blood glucose levels.

Hospira also acquired other assets related to the EndoTool business, including MD Scientific's headquarters in Charlotte, and will hire the employees supporting the product.

MD Scientific was formed in 2003 with the mission, it said, of introducing physician innovation to improve healthcare.

"This acquisition represents an important extension of Hospira's commitment to improved outcomes, patient safety and enhanced clinician efficiency," said Chris Kolber, president, Global Devices, Hospira. "With the market-leading EndoTool in the Hospira portfolio, we are underscoring our commitment to technological leadership in the important area of clinical-decision support systems."

In other dealmaking news: NuView Life Sciences (Park City, Utah) said it has agreed to assume management of Trace Life Sciences (Denton, Texas), including operations of the linear accelerator and cyclotron production facilities in Denton. Terms were not disclosed.

The Trace facility produces Copper-64, Copper- 67, Indium-111, Iodine-123 and Thallium-201 used in molecular imaging and nuclear medicine.

"We are confident that by improving operational efficiencies at Trace, combined with our national sales force, we will provide customers a viable resource for their clinical needs," said Paul Crowe, CEO and chairman of NuView.

NuView says it is focused on developing diagnostic or targeted therapies.